Matthias Kromayer

MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved.

AMSilk GmbH engages in the production of fiber and biopolymers.It offers implant coating, medical devices for OTC wound care, functional cosmetics, cell biology device kits, biosteel spidersilk fibers and spidersilk research license. It serves the biosteel fibers, medical devices, and cosmetic ingredients industry. The firm's materials are to be applied in numerous fields to improve existing products or to develop materials for completely new applications, which could not be realized until now due to the lack of an appropriate material. The company was founded by Axel H. Leimer, Thomas Scheibel, and Lin Römer in 2008 and is headquartered in Planegg, Germany.

BIOCRATES Life Sciences AG operates as a research and technology. It provides metabolic phenotyping services. The firm products are absoluteIDQ p150 kit, p180 kit, sterio17 kit, steroid reagents, biocrates bile acids kit, and steroid kit. The company was founded by Gunther Bonn, Adelbert Roscher, and Hartmut Glossmann in 2002 and is headquartered in Innsbruck, Austria.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany.

iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany.